Preventing bone problems in cancer that spread to the bones
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a new medicine (JMT103) against a standard treatment (zoledronic acid) to see if it is better at preventing bone complications like fractures, pain, or needing radiation or surgery on the bones. It is for people whose cancer has spread to their bones.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have breast, prostate, lung, or another solid tumor that has spread to at least one bone.
- If you have prostate cancer, it must be castration-resistant, meaning hormone therapy is no longer controlling it, and your testosterone level is very low.
- Your overall health is good enough for you to be expected to live at least 6 more months.
- You have not had jaw bone problems (like osteonecrosis), recent jaw surgery, or planned dental surgery during the study.
- You have not used certain bone-strengthening drugs (like bisphosphonates or anti-RANKL antibodies) in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether zoledronic acid, a medicine given by IV, helps prevent bone problems in women with breast cancer that has spread to the bones. It looks at how well the drug works in a real-world setting to reduce the risk of fractures or other bone issues.
This trial tests whether giving radiation to certain bone tumors early can prevent bone problems like fractures or spinal cord pressure. It is for people with solid cancers that have spread to the bones but are not yet causing pain or high-risk damage.
This study tests an experimental medication (JMT103) for people with giant cell tumor of bone that cannot be safely removed with surgery. The drug may help shrink the tumor or slow its growth, providing an option when surgery is too risky.
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
This trial studies how tyrosine kinase inhibitor (TKI) medicines work against non-small cell lung cancer that has spread to the bone. It’s for people with specific “actionable” gene changes, to see how well these treatments reduce or change bone metastases.
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
Hear when a new Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.